Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

This study is testing a new type of immune cell therapy (called CAR-T cell therapy, using donor gamma-delta T cells) for people with a blood cancer called B-cell non-Hodgkin lymphoma (NHL) that has come back or stopped responding to other treatments. The therapy genetically modifies immune cells to attack cancer cells with a protein called CD19. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with CD19-positive B-cell NHL confirmed by a lab test - Your cancer has relapsed or stopped responding after at least 2 previous treatments - You have adequate organ function and general health **You may NOT be eligible if...** - You have active, untreated brain involvement from your cancer - You have serious infections or uncontrolled other diseases - You have received certain prior stem cell transplants or CAR-T therapies that would disqualify you - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.